Angioimmunoblastic T-Cell Lymphoma Management

Kailash Mosalpuria, R. Gregory Bociek, Julie M. Vose

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Angioimmunoblastic T-cell lymphoma (AITL) is a frequent subtype of peripheral T-cell lymphoma (PTCL) that is clinically characterized by generalized lymphadenopathy, extranodal involvement, advanced stage at presentation, hypergammaglobulinemia, and significant immune dysregulation resulting in infections as the most common cause of death. Recent advances in pathobiology of AITL have improved our understanding of it as a clonal T-cell disorder and of its effect on B cells in the tumor microenvironment. Reponses to first-line therapies have largely been dismal. In this review, we discuss the clinical features, pathobiology, prognostic models, standard therapy, and newer therapeutic agents used and their implications for the future.

Original languageEnglish (US)
Pages (from-to)52-58
Number of pages7
JournalSeminars in hematology
Issue number1
StatePublished - Jan 2014

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Angioimmunoblastic T-Cell Lymphoma Management'. Together they form a unique fingerprint.

Cite this